AlloVir Inc. (ALVR): Price and Financial Metrics

AlloVir Inc. (ALVR): $0.75

0.01 (-0.87%)

POWR Rating

Component Grades

Momentum

C

Stability

D

Sentiment

Quality

C

Add ALVR to Watchlist
Sign Up

Industry: Biotech

Industry

F

Ranked

#306 of 365

in industry

ALVR Price/Volume Stats

Current price $0.75 52-week high $6.12
Prev. close $0.76 52-week low $0.62
Day low $0.74 Volume 381,000
Day high $0.79 Avg. volume 1,357,910
50-day MA $0.72 Dividend yield N/A
200-day MA $1.96 Market Cap 86.71M

ALVR Stock Price Chart Interactive Chart >


AlloVir Inc. (ALVR) Company Bio


AlloVir, Inc. engages in the research, development and commercialization of off-the-shelf VST therapies to prevent and treat severe viral-associated diseases. It develops novel cell therapies with a focus on restoring natural immunity against life-threatening virus-associated diseases in patients with severely weakened immune systems. The firm's technology platforms deliver commercially scalable solutions by leveraging off-the-shelf, allogeneic, multi-virus specific T-cells targeting devastating viral pathogens for immunocompromised patients under viral attack. The company was founded by Malcolm K. Brenner, Juan F. Vera, Helen E. Heslop, Cliona M. Rooney, John Wilson, and Ann M. Leen in 2013 and is headquartered in Houston, TX.


ALVR Latest News Stream


Event/Time News Detail
Loading, please wait...

ALVR Latest Social Stream


Loading social stream, please wait...

View Full ALVR Social Stream

Latest ALVR News From Around the Web

Below are the latest news stories about ALLOVIR INC that investors may wish to consider to help them evaluate ALVR as an investment opportunity.

Karuna downgraded, Arm target raised: Wall Street's top analyst calls

Karuna downgraded, Arm target raised: Wall Street's top analyst calls

Yahoo | December 26, 2023

Nike downgraded, Waste Management upgraded: Wall Street's top analyst calls

Nike downgraded, Waste Management upgraded: Wall Street's top analyst calls

Yahoo | December 22, 2023

AlloVir Provides Updates on Phase 3 Clinical Development Program for Posoleucel, an Allogeneic Virus-Specific T Cell Therapy

Company to discontinue its three Phase 3 posoleucel studies following separate, pre-planned DSMB futility analyses concluding the studies were unlikely to meet their primary endpoints; no safety concerns identified Company to prioritize capital preservation and review strategic options AlloVir reported $213.3 million in cash, cash equivalents, and short-term investments as of September 30, 2023 WALTHAM, Mass., Dec. 22, 2023 (GLOBE NEWSWIRE) -- AlloVir, Inc. (Nasdaq: ALVR), an allogeneic T cell i

Yahoo | December 22, 2023

Penny Stock Jackpots: 3 High-Stakes Picks With 10-Bagger Potential

There are penny stocks and then are penny stock picks that are so outrageously wild that they should never be considered unless one is gambling with pocket change.

Josh Enomoto on InvestorPlace | December 5, 2023

AlloVir to Present at the Piper Sandler 35th Annual Healthcare Conference

WALTHAM, Mass., November 16, 2023--AlloVir, Inc. (Nasdaq: ALVR), a late-clinical stage allogeneic T cell immunotherapy company, today announced that Diana Brainard, M.D., Chief Executive Officer, will participate in a fireside chat at the Piper Sandler 35th Annual Healthcare Conference in New York City, NY on Tuesday, November 28, 2023 at 10:00 a.m. ET.

Yahoo | November 16, 2023

Read More 'ALVR' Stories Here

ALVR Price Returns

1-mo 5.04%
3-mo 10.33%
6-mo -65.12%
1-year -81.20%
3-year -96.62%
5-year N/A
YTD 10.33%
2023 -86.75%
2022 -60.36%
2021 -66.34%
2020 N/A
2019 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!